|
|
|
| Research progress on non-human primate models of Parkinson’s disease |
| SONG Jingyang1 CHE Xiangyuan1 XING Hongxia2 |
1.Department of Neurology, the First Affiliated Hospital of Xinxiang Medical University, He’nan Province, Weihui 453100, China;
2.Department of Neurology, the Third Affiliated Hospital of Xinxiang Medical University, He’nan Province, Xinxiang 453000, China |
|
|
|
Abstract Parkinson’s disease (PD) is a common neurodegenerative disease in middle-aged and elderly people. Nowadays, medical science can only delay its progress but cannot cure it. The successful establishment of PD experimental animal model that can simulate the pathogenesis similar to humans is the key link to solve these problems. As for animal models, all kinds of experimental animals have advantages and disadvantages. However, since the physiological and biochemical mechanisms of non-human primates are very similar to those of humans, PD model of non-human primates has become an ideal target. This paper summarizes and analyzes the existing PD animal models, the classical 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) non-human primate PD animal models, and the new PD non-human primate models, so as to discuss the key issues to be considered in the establishment of animal models and the direction of improvement. It is hoped that more scientific modeling methods and more advanced evaluation methods can be found through this review, which will provide some references for the selection and establishment of animal models.
|
|
|
|
|
|
[1] Raza C，Anjum R，Shakeel NUA. Parkinson′s disease：Mechanisms，translational models and management strategies [J]. Life Sci，2019，226：77-90.
[2] Sasaki E. Prospects for genetically modified non-human primate models，including the common marmoset [J]. Neurosci Res，2015，93：110-115.
[3] Dawson TM，Ko HS，Dawson VL. Genetic animal models of Parkinson′s disease [J]. Neuron，2010，66（5）：646-661.
[4] Hamadjida A，Frouni I，Kwan C，et al. Classic animal models of Parkinson′s disease： a historical perspective [J]. Behav Pharmacol，2019，30（4）：291-310.
[5] Santana M，Palmér T，Simplício H，et al. Characterization of long-term motor deficits in the 6-OHDA model of Parkinson′s disease in the common marmoset [J]. Behav Brain Res，2015，290：90-101.
[6] Chia SJ，Tan EK，Chao YX. Historical Perspective：Models of Parkinson′s Disease [J]. Int J Mol Sci，2020，21（7）：2464.
[7] Abushouk AI，Negida A，Ahmed H，et al. Neuroprotective mechanisms of plant extracts against MPTP induced neurotoxicity：Future applications in Parkinson′s disease [J]. Biomed Pharmacother，2017，85：635-645.
[8] Halliday G，Herrero MT，Murphy K，et al. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism [J]. Mov Disord，2009，24（10）：1519-1523.
[9] Ono K. The Oligomer Hypothesis in α-Synucleinopathy [J]. Neurochem Res，2017，42（12）：3362-3371.
[10] Jackson-Lewis V，Przedborski S. Protocol for the MPTP mouse model of Parkinson′s disease [J]. Nat Protoc，2007， 2（1）：141-151.
[11] Ando K，Inoue T，Hikishima K，et al. Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson′s disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine：providing reference data for efficacious preclinical evaluations [J]. Behav Pharmacol，2020，31（1）：45-60.
[12] Hernandez-Baltazar D，Zavala-Flores LM，Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology： Novel findings in an older model [J]. Neurologia，2017，32（8）：533-539.
[13] Blum D，Torch S，Lambeng N，et al. Molecular pathways involved in the neurotoxicity of 6-OHDA，dopamine and MPTP：contribution to the apoptotic theory in Parkinson′s disease [J]. Prog Neurobiol，2001，65（2）：135-172.
[14] Metzger JM，Moore CF，Boettcher CA，et al. In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration [J]. NPJ Parkinsons Dis，2018，4：22.
[15] Joers V，Dilley K，Rahman S，et al. Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates [J]. PLoS One，2014，9（8）：e104850.
[16] Kumar V，Singh D，Singh BK，et al. Alpha-synuclein aggregation，Ubiquitin proteasome system impairment，and L-Dopa response in zinc-induced Parkinsonism：resemblance to sporadic Parkinson′s disease [J]. Mol Cell Biochem，2018，444（1/2）：149-160.
[17] McNaught KS，Perl DP，Brownell AL，et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson′s disease [J]. Ann Neurol，2004，56（1）：149-162.
[18] Savolainen MH，Albert K，Airavaara M，et al. Nigral injection of a proteasomal inhibitor，lactacystin，induces widespread glial cell activation and shows various phenotypes of Parkinson′s disease in young and adult mouse [J]. Exp Brain Res，2017，235（7）：2189-2202.
[19] Bentea E，Verbruggen L，Massie A. The Proteasome Inhibition Model of Parkinson′s Disease [J]. J Parkinsons Dis，2017，7（1）：31-63.
[20] Lim KL. Ubiquitin-proteasome system dysfunction in Parkinson′s disease：current evidence and controversies [J]. Expert Rev Proteomics，2007，4（6）：769-781.
[21] Lillethorup TP，Glud AN，Alstrup AKO，et al. Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs [J]. Sci Rep，2018，8（1）：15715.
[22] Matsui H，Ito H，Taniguchi Y，et al. Proteasome inhibition in medaka brain induces the features of Parkinson′s disease [J]. J Neurochem，2010，115（1）：178-187.
[23] McNaught KS, Bj?觟rklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. [J]. Neuroreport, 2002,13（11）：1437-1441.
[24] Liu Y，Yue F，Tang R，et al. Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging（[（18）F]AV-133）[J]. Neurosci Bull，2014，30（3）：409-416.
[25] Monje MHG，Blesa J，García-Cabezas M?觃?魣，et al. Changes in thalamic dopamine innervation in a progressive Parkinson′s disease model in monkeys [J]. Mov Disord，2020，35（3）：419-430.
[26] Li S，Jamadar SD，Ward PGD，et al. Analysis of continuous infusion functional PET（fPET）in the human brain [J]. Neuroimage，2020，213：116720.
[27] Stark AJ，Smith CT，Petersen KJ，et al. [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson′s disease [J]. Neuroimage Clin，2018， 18：433-442.
[28] Saiki H，Hayashi T，Takahashi R，et al. Objective and quantitative evaluation of motor function in a monkey model of Parkinson′s disease [J]. J Neurosci Methods，2010，190（2）：198-204.
[29] Saeed U，Compagnone J，Aviv RI，et al. Imaging biomarkers in Parkinson′s disease and Parkinsonian syndromes： current and emerging concepts [J]. Transl Neurodegener，2017，6：8.
[30] Gr?觟ger A，Kolb R，Sch?覿fer R，et al. Dopamine reduction in the substantia nigra of Parkinson′s disease patients confirmed by in vivo magnetic resonance spectroscopic imaging [J]. PLoS One，2014，9（1）：e84081.
[31] Lai JH，Chen KY，Wu JC，et al. Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson′s disease [J]. Brain Res，2019，1720：146301. |
|
|
|
